Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • APR 05 2018

    Musella Foundation About ONC201 Clinical Trials in Pediatric and Adult Patients with H3 K27M Glioma

    Brain Tumor News Blast Issue 5,656 (Wednesday, April 4, 2018): ONC201 is an experimental, orally bioavailable, first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. It is currently investigated for its safety and efficacy in the following clinical trials: 1) ONC-201 for Recurrent Glioblastomas